Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-M vs Ultrix in Children Aged 6-17 Years
NCT05317767Phase 3Completed
- Sponsor
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Start
- Feb 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza (2 arms), sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Primary endpoints: Geometric Mean Titer at 28 days, Seroconversion Rate at 28 days and 2 more. Started Feb 2020; status: completed.
02
Drugs
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05317767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317767.